Teva Pharmaceuticals will fund R&D for a drug delivery platform to be developed by Jexys Pharmaceuticals.
Release content courtesy of Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem
Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, announced this week that its subsidiary Jexys Pharmaceuticals has signed a strategic research and development agreement with Teva Pharmaceuticals Industries Ltd. Under the terms of the agreement, Teva will finance Jexys' R&D program for the development of a high throughput drug discovery platform and in return will receive a minority equity interest in Jexys Pharmaceuticals. Following the completion of the program, Teva will have the option to in-license 5 drug candidates discovered by Jexys, according to Teva's choice. This agreement is an extension of a collaborative agreement, signed in October 2006 between Jexys and Teva Pharmaceuticals.